Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized trial of pertuzumab with or without trastuzumab in HER2-positive, hormone receptor–positive advanced breast cancer
2011-002132-10Phase 2Completed
- Sponsor
- Roche
- Start
- Oct 2011
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in breast cancer comparing Pertuzumab monotherapy with Pertuzumab + trastuzumab (2 arms). Primary endpoint: Progression-Free Survival. Started Oct 2011; status: completed.
02
Drugs
pertuzumabtrastuzumab
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2011-002132-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-002132-10.